– Record total revenues of $4.1 billion in 2024 and $1.1 billion in 4Q24 –
– Xywav® and Epidiolex® revenues grew 16% and 15% year-over-year, respectively, in 2024 –– Oncology revenues grew 9% year-over-year in 2024, surpassed $1.1 billion –
– Ziihera® approved in 2L HER2+ (IHC3+) BTC; first sales achieved in December 2024 –
– 2025 guidance reflects continued top- and bottom-line growth –
Jazz Pharmaceutical's full year 2025 financial guidance is as follows:
(In millions) | Guidance | ||
Total Revenues | $4,150 - $4,400 | ||
(In millions, except per share amounts and percentages) | GAAP | Non-GAAP | |
Gross margin % | 88 % | 92%1,6 | |
SG&A expenses | $1,404 - $1,483 | $1,250 - $1,3102,6 | |
R&D expenses | $792 - $851 | $720 - $7703,6 | |
Effective tax rate | (5)% - 10% | 13% - 15%4,6 | |
Net income | $560 - $720 | $1,400 - $1,5005,6 | |
Net income per diluted share | $9.15 - $11.50 | $22.50 - $24.005,6 | |
Weighted-average ordinary shares used in per share calculations | 62 - 63 | 62 - 63 | |
Jazz Pharmaceuticals will host an investor conference call and live audio webcast today at 4:30 p.m. ET (9:30 p.m. GMT) to provide a business and financial update and discuss its 2024 full year and 4Q24 results and 2025 guidance.
Audio webcast/conference call:
U.S. Dial-In Number: +1 800 715 9871
Ireland Dial-In Number: +353 1800 943 926
Additional global dial-in numbers are available here.
Passcode: 5080203
Interested parties may access the live audio webcast via the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast.
A replay of the webcast will be available via the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.